TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Hydra TAVR valve gains key approval as global reach continues to grow
The self-expanding device is now available in more than 20 countries and received CE mark approval back in 2020. However, it has not yet been approved by the U.S. Food and Drug Administration for use in the United States.
SAVR outperforms TAVR in patients with bicuspid aortic valves
BAV patients are often excluded from TAVR trials, creating uncertainty about the best way to treat that population when aortic valve replacement is required. To learn more, researchers tracked CMS data from 2018 to 2022, presenting their findings in The Annals of Thoracic Surgery.
Treating AFib patients with TAVR still linked to elevated risks
While the technology and techniques associated with TAVR have advanced over the years, treating patients who present with baseline atrial fibrillation is still associated with certain risks.
Years of progress have made TAVR more effective when treating concomitant mitral stenosis
Newer balloon-expandable TAVR valves are associated with much better outcomes for patients presenting with both severe AS and severe MS than older models.
TAVR/PCI bests SAVR/CABG when treating severe AS and complex CAD
Percutaneous treatment was linked to improved survival and fewer adverse events than surgery when patients presented with both symptomatic severe aortic stenosis and complex coronary artery disease.

An updated look at how cognitive impairment affects TAVR outcomes

The connection between cognitive impairment and postoperative delirium among TAVR patients stood out as a definite concern to the study's authors.

October 13, 2022

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

Severe prosthesis-patient mismatch after TAVR linked to a higher risk of death

Researchers examined data from 82,000 TAVR patients, focusing on echocardiography-defined PPM. They shared their results in JACC: Cardiovascular Imaging.

October 11, 2022

5 key predictors of heart failure hospitalizations after TAVR

Diabetes and atrial fibrillation are just some of the factors that can increase a patient's risk of being hospitalized for heart failure within one year of undergoing a successful TAVR procedure.

October 6, 2022